REV-200 (Revitope Oncology)

N/A

Report date: 2026/03/19 16:57:30

Base Information

Drug NameREV-200 (Revitope Oncology)
Drug Alias NameAnti-CD3/Undisclosed Target Bispecific T-cell Engager Antibody (Revitope Oncology/Junshi Biosciences)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesRevitope Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesRevitope Oncology IncShanghai Junshi Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A